Congress may reexamine the amount of funds allocated to the device user fee program in the omnibus FY 2003 spending bill, following the Feb. 3 release of President Bush's FY 2004 budget request, which designates only $1 mil. for premarket review activities at CDRH
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.
